This HTML5 document contains 44 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n14http://linked.opendata.cz/resource/mesh/concept/
n8http://linked.opendata.cz/resource/drugbank/drug/DB08794/identifier/chemspider/
n12http://bio2rdf.org/drugbank:
n6http://linked.opendata.cz/resource/drugbank/drug/DB08794/identifier/chebi/
admshttp://www.w3.org/ns/adms#
n15http://linked.opendata.cz/resource/drugbank/drug/DB08794/identifier/wikipedia/
n11http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n13http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n9http://linked.opendata.cz/resource/drugbank/drug/DB08794/identifier/drugbank/

Statements

Subject Item
n2:DB08794
rdf:type
n3:Drug
n3:description
Ethyl biscoumacetate is a courmarin that is used as an anticoagulant. It has actions similar to those of Warfarin. (From Martindale, The Extra Pharmacopoeia, 30th ed, p226)
n3:group
withdrawn
owl:sameAs
n11:DB08794 n12:DB08794
dcterms:title
Ethyl biscoumacetate
adms:identifier
n6:231177 n8:10579 n9:DB08794 n15:Ethyl_biscoumacetate
n3:synonym
Tromexan Pelentan
n3:synthesisReference
Rosicky, J.; U.S. Patent 2,482,511; September 20,1949; assigned to Spojene Farmaceuticke Zovody (Czechoslovakia).
n13:hasConcept
n14:M0007891
n3:IUPAC-Name
n4:271B5488-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B548E-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B548D-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B548A-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B548B-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B548C-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B549E-363D-11E5-9242-09173F13E4C5 n4:271B5486-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B5484-363D-11E5-9242-09173F13E4C5 n4:271B5487-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B5485-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B5494-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B5495-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B548F-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B5490-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B5492-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B5491-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B5493-363D-11E5-9242-09173F13E4C5
n3:casRegistryNumber
548-00-5
n3:category
n3:Bioavailability
n4:271B549A-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B549C-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B549D-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B549F-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B5499-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B5498-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B549B-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B5489-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B5496-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B5497-363D-11E5-9242-09173F13E4C5